Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Biomarin Pharmaceutical stock
Learn how to easily invest in Biomarin Pharmaceutical stock.
Biomarin Pharmaceutical Inc is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Biomarin Pharmaceutical employs 3,045 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Biomarin Pharmaceutical
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BMRN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- BMRN shares summary
- Compare share dealing platforms
- Is BMRN stock a buy or sell?
- Stock performance over time
- Is BMRN suitable for ethical investing?
- Are BMRN shares over-valued?
- Biomarin Pharmaceutical's financials
- How volatile are BMRN shares?
- Does Biomarin Pharmaceutical pay a dividend?
- Other common questions
Biomarin Pharmaceutical stock price (NASDAQ: BMRN)Use our graph to track the performance of BMRN stocks over time.
Biomarin Pharmaceutical shares at a glance
|Latest market close||$84.98|
|52-week range||$70.73 - $94.20|
|50-day moving average||$79.15|
|200-day moving average||$81.73|
|Wall St. target price||$112.61|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.19|
Buy Biomarin Pharmaceutical shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Biomarin Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biomarin Pharmaceutical price performance over time
|1 week (2022-06-27)||-0.13%|
|1 month (2022-06-02)||12.26%|
|3 months (2022-03-31)||10.22%|
|6 months (2022-01-04)||-2.57%|
|1 year (2021-07-02)||-0.57%|
|2 years (2020-07-02)||-32.97%|
|3 years (2019-07-03)||0.99%|
|5 years (2017-07-03)||90.51|
Is Biomarin Pharmaceutical stock undervalued or overvalued?
Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biomarin Pharmaceutical's P/E ratio
Biomarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 447x. In other words, Biomarin Pharmaceutical shares trade at around 447x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Biomarin Pharmaceutical's PEG ratio
Biomarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8321. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biomarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biomarin Pharmaceutical's EBITDA
Biomarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $37.1 million.
The EBITDA is a measure of a Biomarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
Biomarin Pharmaceutical financials
|Revenue TTM||$1.9 billion|
|Gross profit TTM||$1.4 billion|
|Return on assets TTM||-0.74%|
|Return on equity TTM||0.92%|
|Market capitalisation||$15.7 billion|
TTM: trailing 12 months
Biomarin Pharmaceutical's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biomarin Pharmaceutical.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Biomarin Pharmaceutical's total ESG risk score
Total ESG risk: 25.92
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biomarin Pharmaceutical's overall score of 25.92 (as at 12/31/2018) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Biomarin Pharmaceutical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Biomarin Pharmaceutical's environmental score
Environmental score: 0.12/100
Biomarin Pharmaceutical's environmental score of 0.12 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Biomarin Pharmaceutical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Biomarin Pharmaceutical's social score
Social score: 15.87/100
Biomarin Pharmaceutical's social score of 15.87 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Biomarin Pharmaceutical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Biomarin Pharmaceutical's governance score
Governance score: 7.42/100
Biomarin Pharmaceutical's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Biomarin Pharmaceutical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Biomarin Pharmaceutical's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Biomarin Pharmaceutical scored a 1 out of 5 for controversy – the highest score possible, reflecting that Biomarin Pharmaceutical has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||25.92|
|Total ESG percentile||42.26|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
Biomarin Pharmaceutical share dividends
We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.
Biomarin Pharmaceutical share price volatility
Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $70.73 up to $94.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.4179. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).
Biomarin Pharmaceutical overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U. S.
Biomarin Pharmaceutical in the news
BioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
Frequently asked questionsWhat percentage of Biomarin Pharmaceutical is owned by insiders or institutions?
Currently 0.567% of Biomarin Pharmaceutical shares are held by insiders and 98.473% by institutions. How many people work for Biomarin Pharmaceutical?
Latest data suggests 3,045 work at Biomarin Pharmaceutical. When does the fiscal year end for Biomarin Pharmaceutical?
Biomarin Pharmaceutical's fiscal year ends in December. Where is Biomarin Pharmaceutical based?
Biomarin Pharmaceutical's address is: 770 Lindaro Street, San Rafael, CA, United States, 94901 What is Biomarin Pharmaceutical's ISIN number?
Biomarin Pharmaceutical's international securities identification number is: US09061G1013 What is Biomarin Pharmaceutical's CUSIP number?
Biomarin Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 09061G101
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert